Scientists have developed a method to reprogram cancer-fighting immune cells directly inside the body, potentially ...

For patients who have spent years managing unpredictable and debilitating autoimmune conditions like lupus, the findings ...

CLEVELAND, Ohio — A shift toward personalized treatment for breast cancer, ways to help patients live longer without their ...

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel ...

A triple drug approach that blocks the KRAS pathway at three points eliminated pancreatic tumors and prevented resistance in ...

Vermont Business Magazine The University of Vermont Cancer Center is the first in Vermont to begin using a revolutionary new ...

Chemotherapy-induced myelosuppression (CIM) remains one of the most significant and underappreciated barriers to delivering ...

The 2026 NCCN Bladder Cancer Guidelines incorporate the IBCG five-factor model, introducing standardized risk stratification for intermediate-risk NMIBC. For decades, heterogeneity in ...

In this study, researchers aimed to determine whether the addition of durvalumab to gemcitabine plus cisplatin increases time toxicity.

Cardiovascular disease is the second leading cause of death among cancer survivors, second only to cancer itself. The same treatments that can save patients from cancer may also r ...

The Barbara Ann Karmanos Cancer Institute in Detroit has become the first and only independent cancer center in the U.S. to ...

The chances of breast cancer recurring remain very low when patients are treated with radiotherapy that is tailored to their ...